• Target

    £5,000,000

  • Type

    Equity

  • Close Date

    May 1 2019

  • Status

    Live

RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.

Cambridge Medical Technologies Limited

CMT has developed a lab-on-a-chip on a Band-Aid that continuously and imperceptibly monitors certain blood biomarkers present in intercellular fluid j

A pledge is not a commitment. You will be asked to confirm in the next section.

Track
Contact
Companies
House
Twitter

Overview

Globally the blood testing market is anticipated to reach 62.9bn USD  by 2024 (Grand View Research, June 2016). This growth has largely been owed to a growing adaptation of testing and screening methodologies that improve near patient diagnosis through enhanced blood testing that reduces diagnostic turnarounds and lower hospitals stay durations.
 
Traditionally blood biomarkers have been used as indicators of health and have been deducted through invasive blood tests. This process requires a nurse to puncture the blood vessels in order to draw the blood and a lab is required to render an analysis. Furthermore, the process requires the patient to follow up regarding his/her results. The blood drawn only reflects the patient’s condition at the time. 
 
As a solution, Cambridge Medical Technologies Limited (CMT), has designed an electronic chip that imperceptibly conducts tests for blood biomarkers and wirelessly communicates the results to physicians, enabling the real time monitoring of trends relating to medical condition – regardless of patient location.
 
CMT’s technology will enable the patients’ blood to continuously be analysed, with real time updates and alerts being communicated to the health technician’s smart phone or tablet. The data is also electronically inputted into the patient’s medical records. Such a device will dramatically the cost of healthcare. 
Deal Manager avatar

Deal Manager
Sonal Shah

  • Sector: Healthcare
  • Region: UK: South-East
  • Stage: Early stage - early revenues, pre-profit
  • Eligible Tax: EIS
  • Board Requirement: Will consider further board appointments
  • Pre Money Valuation: £25,000,000
  • Share Price: £82.50
  • Originator: Cambridge Medical Technologies
This section is currently locked.
Please Sign Up or Log In to unlock.

Team

This section is currently locked.
Please Sign Up or Log In to unlock.

Investment

This section is currently locked.
Please Sign Up or Log In to unlock.

Discussions

This section is currently locked.
Please Sign Up or Log In to unlock.

Documents

This section is currently locked.
Please Sign Up or Log In to unlock.

Originator


Originator: Cambridge Medical Technologies

Deal Type: Equity

Geographical Focus: UK, Europe, and China

About: Cambridge Medical Technologies Limited (CMT), has designed an electronic chip that imperceptibly conducts tests for blood biomarkers and wirelessly communicates the results to physicians, enabling the real time monitoring of trends relating to medical condition - regardless of patient location.

Type: Company raising finance

Contact Name: James Cooke

Date established: September 2014

Date Joined Envestry: February 2019